Critical Contrast: Statera Biopharma (STAB) and Its Rivals

Profitability

This table compares Statera Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Statera Biopharma Competitors	-2,625.49%	-359.57%	-43.35%

Institutional & Insider Ownership

39.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 5.5% of Statera Biopharma shares are held by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Statera Biopharma has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Statera Biopharma’s rivals have a beta of 10.21, suggesting that their average share price is 921% more volatile than the S&P 500.

Earnings and Valuation

This table compares Statera Biopharma and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	0.00
Statera Biopharma Competitors	$440.95 million	-$69.10 million	-10.17

Statera Biopharma’s rivals have higher revenue, but lower earnings than Statera Biopharma. Statera Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Statera Biopharma Company Profile

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.